Argenx Se (ARGX) Gross Margin (2022 - 2026)
Argenx Se's (ARGX) quarterly Gross Margin came in at 90.68% in Q2 2026, up 236.0% YoY from 26.99% in Q2 2025, and little changed on a QoQ basis from 90.68% in Q1 2026.
Analysis
Argenx Se (ARGX) Gross Margin (2022 - 2026) Analysis & Trends
Argenx Se (ARGX) has 5 years of Gross Margin data on file, last reported at 90.68% in Q2 2026.
- Quarterly Gross Margin rose 236.0% year-over-year to 90.68% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 90.03% (up 64.0% YoY) and the FY2025 annual result came in at 89.39%, down 52.0% from the prior year.
- Gross Margin was little changed at 90.68% in Q2 2026, from 90.68% in the prior quarter.
- In the past five years, Gross Margin ranged from a high of 93.52% in Q1 2022 to a low of 88.33% in Q2 2025.
- A 5-year average of 90.5% and a median of 90.22% in 2024 frame the typical range for Gross Margin.
- Annual changes were most pronounced in 2023 — Gross Margin tumbled 317 bps — and 2026, when it soared 236 bps.
- Tracing ARGX's Gross Margin over 5 years: stood at 92.63% in 2022, then slipped by 3 bps to 89.45% in 2023, then gained by 1 bps to 90.14% in 2024, then dropped by 2 bps to 88.36% in 2025, then gained by 3 bps to 90.68% in 2026.
- The last three Gross Margin figures came in at 90.68% (Q2 2026), 90.68% (Q1 2026), and 88.36% (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.22 Bn | 132.37 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 86.04 Bn | 78.05 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 63.70 Bn | 58.52 Bn | 1.37 Bn | 90.43% |
| 4 | Moderna | 57.56 Bn | 52.42 Bn | 52.00 Mn | 35.86% |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 40.16 Bn | 35.06 Bn | 1.53 Bn | 89.76% |
| 7 | Alnylam Pharmaceuticals | 35.63 Bn | 32.32 Bn | 992.69 Mn | 76.90% |
| 8 | Royalty Pharma | 28.63 Bn | 27.79 Bn | - | - |
| 9 | Insmed | 27.73 Bn | 26.57 Bn | 358.27 Mn | 84.20% |
| 10 | Incyte | 25.60 Bn | 21.07 Bn | 1.57 Bn | 93.73% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 90.43% |
| Mar 31, 2026 | 90.68% |
| Dec 31, 2025 | 88.36% |
| Sep 30, 2025 | 90.29% |
| Jun 30, 2025 | 88.33% |
| Mar 31, 2025 | 89.75% |
| Dec 31, 2024 | 90.14% |
| Sep 30, 2024 | 89.69% |
| Jun 30, 2024 | 89.03% |
| Mar 31, 2024 | 89.16% |
| Dec 31, 2023 | 89.45% |
| Sep 30, 2023 | 89.06% |
| Jun 30, 2023 | 91.08% |
| Mar 31, 2023 | 91.59% |
| Dec 31, 2022 | 92.63% |
| Sep 30, 2022 | 92.18% |
| Jun 30, 2022 | 93.31% |
| Mar 31, 2022 | 93.52% |